Summary by Moomoo AI
Marc Banjak, Chief Legal Officer of iBio Inc, filed an Initial Statement of Beneficial Ownership of Securities with the SEC on August 14, 2024. The filing, required under Section 16(a) of the Securities Exchange Act of 1934, details Banjak's direct ownership of non-derivative and derivative securities in the company. The non-derivative securities include 1,875 shares of common stock represented by restricted stock units (RSUs) that vested quarterly over 12 months, with the final tranche vesting on March 31, 2024. Additionally, the filing outlines multiple stock options with varying vesting schedules and exercise prices, including options for 800 shares at $170.4, 600 shares at $141.2, 3,000 shares at $6.92, 29,000 shares at $1.72, and 55,000 shares at $1.88. These options have exercise periods ranging from 2022 to 2034 and are contingent upon Banjak's continued employment with iBio Inc.
